-
公开(公告)号:WO2004092163A1
公开(公告)日:2004-10-28
申请号:PCT/JP2004/005237
申请日:2004-04-13
IPC分类号: C07D405/12
CPC分类号: C07D405/12 , A61K31/4155 , A61K31/4178 , C07D409/12 , C07D411/12
摘要: A compound represented by the formula (1): wherein R represents hydrogen or optionally substituted C1-6 alkyl; A represents imidazolyl or pyrazolyl; B represents a group represented by the formula (2) (wherein R5 and R6 each independently represents hydrogen, cyano, hydroxy, halogeno, C1-6 alkyl, C1-6 alkoxy, etc.; and k is an integer of 0 to 15, provided that when k is 2 or larger, then the R5's and R6's each may be the same or different); and Z represents substituted chroman-2-yl, substituted 2,3-dihydrobenzofuran-2-yl, substituted thiochroman-2-yl, substituted 2,3-dihydrobenzothiophen-2-yl, or substituted 1,3-benzoxanthiol-2-yl. Also provided are a process for producing the compound; an antioxidant drug containing the compound as an active ingredient; and a therapeutic agent for kidney disorders, therapeutic agent for cerebrovascular disorders, inhibitor for retinal oxidation disorders, lipoxygenase inhibitor, and 20-HETE production synthase inhibitor which each contains the antioxidant drug.
摘要翻译: 由式(1)表示的化合物:其中R表示氢或任选取代的C 1-6烷基; A表示咪唑基或吡唑基; B表示由式(2)表示的基团(其中R 5和R 6各自独立地表示氢,氰基,羟基,卤代C 1-6烷基,C 1-6烷氧基等; k为0〜15的整数, 条件是当k为2或更大时,则R5和R6各自可以相同或不同); Z表示取代的苯并二氢吡喃-2-基,取代的2,3-二氢苯并呋喃-2-基,取代的二氢苯并噻喃-2-基,取代的2,3-二氢苯并噻吩-2-基或取代的1,3-苯并氧基山梨醇-2-基 。 还提供了制备该化合物的方法; 含有该化合物作为活性成分的抗氧化剂药物; 和用于肾脏疾病的治疗剂,脑血管病症治疗剂,视网膜氧化病症抑制剂,脂氧合酶抑制剂和20-HETE生产合成酶抑制剂,其各自含有抗氧化剂药物。
-
公开(公告)号:WO2004092153A1
公开(公告)日:2004-10-28
申请号:PCT/JP2004/005240
申请日:2004-04-13
IPC分类号: C07D307/79
CPC分类号: C07D307/79 , C07D311/70
摘要: A compound represented by the formula (1): (wherein R1, R2, R3, and R4 each independently represents hydrogen or C1-6 alkyl and n is an integer of 1 or 2); a process for producing the compound; an antioxidizing drug containing the compound as an active ingredient; and a therapeutic drug for renal diseases, therapeutic drug for cerebrovascular disorders, inhibitory drug for retinal oxidation disorders, and lipoxygenase inhibitory drug each containing the antioxidizing drug.
摘要翻译: 由式(1)表示的化合物:其中R1,R2,R3和R4各自独立地表示氢或C1-6烷基,n是1或2的整数); 一种制备该化合物的方法; 含有该化合物作为活性成分的抗氧化剂; 以及肾脏疾病治疗药,脑血管障碍治疗药,视网膜氧化障碍用抑制药和各自含有抗氧化药物的脂氧合酶抑制药。
-
公开(公告)号:WO2004092179A1
公开(公告)日:2004-10-28
申请号:PCT/JP2004/005231
申请日:2004-04-13
IPC分类号: C07D491/107
CPC分类号: C07D493/10 , A61K31/438
摘要: A compound represented by the formula (1): (wherein R1, R2, and R3 each independently represents hydrogen or C1-8 alkyl; bond A-B represents the formula -CH2-CH2-, -CH=CH-, etc.; and X represents oxygen, sulfur, etc.) or a pharmaceutically acceptable salt thereof; and a process for producing the compound or salt. Also provided are: an antioxidant containing the compound as an active ingredient; and a therapeutic agent for kidney diseases or cerebrovascular disorders, a depressant for retinal oxidation disorders, and a lipoxygenase inhibitor which each comprises the antioxidant.
摘要翻译: 由式(1)表示的化合物:其中R1,R2和R3各自独立地表示氢或C1-8烷基;键AB表示式-CH2-CH2-,-CH = CH-等;和X 表示氧,硫等)或其药学上可接受的盐; 和该化合物或盐的制造方法。 还提供:含有该化合物作为活性成分的抗氧化剂; 以及用于肾脏疾病或脑血管病症的治疗剂,视网膜氧化病症抑制剂和脂氧合酶抑制剂,其各自包含抗氧化剂。
-
公开(公告)号:WO2005012293A1
公开(公告)日:2005-02-10
申请号:PCT/JP2004/011297
申请日:2004-07-30
IPC分类号: C07D405/12
CPC分类号: C07D471/04 , C07D405/12 , C07D405/14
摘要: Compounds represented by the general formula (1) or pharmaceutically acceptable salts thereof; and antioxidants, remedies for kidney diseases or cerebrovascular disorder, or retinal oxidative damage inhibitors, containing the compounds as the active ingredient: B - D - Z (1) wherein B is a group represented by the following general formula (B-1), (B-2), or (B-3): A is optionally substituted imidazolyl or pyrazolyl; E is a group represented by the general formula (1a) or the like: (1a) X is O, SOu, or N-R9; Y is carbon or nitrogen; D is oxygen, sulfur, or a group of the general formula (1a); Z is an NHR10- or OR11-substituted, chroman-2-yl, chroman-4-yl, 2,3-dihydro- benzofuran-2-yl, or 2,3-dihydrobenzofuran-3-yl group or the like.
摘要翻译: 由通式(1)表示的化合物或其药学上可接受的盐; 含有该化合物作为活性成分的抗氧化剂,肾脏疾病或脑血管障碍的补救剂或视网膜氧化损伤抑制剂:B-D-Z(1)其中B是由以下通式(B-1)表示的基团, (B-2)或(B-3):A是任选取代的咪唑基或吡唑基; E是由通式(1a)等表示的基团:(1a)X是O,SOu或N-R 9; Y为碳或氮; D是氧,硫或通式(1a)的基团; Z是NHR 10或OR 11取代的色满-2-基,色满-4-基,2,3-二氢 - 苯并呋喃-2-基或2,3-二氢苯并呋喃-3-基等。
-
公开(公告)号:WO2003035653A1
公开(公告)日:2003-05-01
申请号:PCT/JP2002/011028
申请日:2002-10-24
IPC分类号: C07D495/14
CPC分类号: C07D495/14 , A61K31/519 , A61K31/5377
摘要: A novel thienopyrimidine compound represented by the formula (1), which is useful as a medicine, especially a cGMP−PDE inhibitor: (1) wherein A represents optionally substituted pyridyl or pyrazolyl; and B represents amidino, di(C 1−6 alkyl)carbamoyl, di(C 1−6 alkyl)sulfamoyl, or a group represented by the formula −Y−G (wherein Y represents carbonyl or sulfonyl; and G represents an optionally substituted, 5− or 6−membered, (un)saturated heterocyclic group containing one to three nitrogen, oxygen, or sulfur atoms).
摘要翻译: 一种由式(1)表示的新型噻吩并嘧啶化合物,其可用作药物,特别是cGMP-PDE抑制剂:(1)其中A表示任选取代的吡啶基或吡唑基; B表示脒基,二(C 1-6烷基)氨基甲酰基,二(C 1-6烷基)氨磺酰基,或由式-Y-G表示的基团 (其中Y表示羰基或磺酰基; G表示含有一至三个氮,氧或硫原子的任选取代的5元或6元饱和杂环基)。
-
-
-
-